BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antares Pharma, Inc. (AIS) Appoints Jonathan S. Jaffe MD Vice President of Clinical Development


7/2/2012 10:43:28 AM

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Jonathan S. Jaffe MD to the position of Vice President of Clinical Development. Jonathan’s background includes a 12 year post-graduate career in academic medicine and more than 15 years of experience in global drug development in the pharmaceutical industry.

“We are very pleased to add another experienced pharmaceutical executive to the Antares development team,” said Kaushik J. Dave R.Ph., Ph.D., and Executive Vice President Product Development. “Jonathan’s previous broad experience as a pharmaceutical clinician will be extremely valuable as we continue to execute on the development of our pipeline products.”

Dr. Jaffe received a Bachelor of Arts degree in Biology from Lehigh University and an MD from the Jefferson Medical College of Thomas Jefferson University in Philadelphia. He completed a residency in Internal Medicine at Lenox Hill Hospital, followed by clinical and laboratory fellowships at the Laboratory of Clinical Investigation, NIAID, NIH, while in the Research Officers Group of the Public Health Service. Following fellowship, Dr Jaffe served on the full-time academic faculty of Hahnemann (now Drexel) University Medical School where he conducted research, taught in the clinics and provided medical care. In 1996 Dr Jaffe began his pharmaceutical career, conducting clinical studies in a variety of transplant indications for Wyeth-Ayerst Research, led global clinical development programs, conducting all phases of research, for respiratory, transplant and autoimmune indications at Schering Plough Research Institute, Novartis, and Forest Research Institute. Immediately prior to joining Antares, Dr Jaffe served on a consulting basis for Pharmanet-i3 as a clinical program leader in inflammatory bowel disease in Pfizer’s Bio-therapeutics Unit. His work on clinical development programs has resulted or contributed to multiple regulatory approvals of compounds both in the US and abroad including Rapamune, Remicade, Xolair, Zortress, and Daliresp.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) marketed by Watson Pharmaceuticals, Inc. in the U.S. Antares’ portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the development and manufacturing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

Contacts

Antares Pharma, Inc.

Jack Howarth

Vice President, Corporate Affairs

609-359-3016

jhowarth@antarespharma.com

or

Westwicke Partners, LLC

John Woolford

443-213-0506

john.woolford@westwicke.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES